Clinical Trials Logo

Clinical Trial Summary

To compare a "liberal" and a "restrictive" strategy to administer blood transfusions in critically ill patients with a primary brain injury.


Clinical Trial Description

Although blood transfusions can be lifesaving in severe hemorrhage, they can also have potential complications. As anemia has also been associated with poor outcomes in critically ill patients, determining an optimal transfusion trigger is a real challenge for clinicians. This is even more important in patients with acute brain injury who were not specifically evaluated in previous large randomized clinical trials dealing with the optimal transfusion threshold. Neurological patients may be particularly sensitive to anemic brain hypoxia because of the exhausted cerebrovascular reserve, which adjusts cerebral blood flow to tissue oxygen demand. This prospective, multicenter, randomized, pragmatic trial will compare two different strategies for red blood cell transfusion in patients with acute brain injury: a "liberal" strategy in which the aim is to maintain hemoglobin (Hb) concentrations greater than 9 g/dL and a "restrictive" approach in which the aim is to maintain Hb concentrations greater than 7 g/dL. The target population is patients suffering from traumatic brain injury (TBI), subarachnoid hemorrhage (SAH) or intracranial hemorrhage (ICH). The primary outcome is neurological outcome, evaluated using the extended Glasgow Outcome Scale (eGOS), at 180 days after the initial injury. Secondary outcomes include, amongst others, 28-day survival, intensive care unit (ICU) and hospital lengths of stay, the occurrence of extra-cerebral organ dysfunction/failure and the development of any infection or thromboembolic events (venous or arterial). The estimated sample size is 794 patients to demonstrate a reduction in the primary outcome (i.e. unfavorable neurological outcome) from 50% to 30% between groups (397 patients in each arm). The study will be initiated in September 2016 in several European ICUs and is expected at least 6 years. The results of this trial will help to improve blood product and transfusion use in this specific patient population and will provide additional data in some sub-groups of patients at high-risk of brain ischemia, such as those with intracranial hypertension or cerebral vasospasm. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02968654
Study type Interventional
Source Erasme University Hospital
Contact
Status Completed
Phase N/A
Start date September 13, 2016
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT01136590 - Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery Phase 4
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005319 - Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00000581 - Granulocyte Transfusion Study Phase 3
Completed NCT04089865 - Oral Versus Intravenous Tranexamic Acid Phase 4
Enrolling by invitation NCT06019364 - Transfusion of Whole Blood in Acute Bleeding
Completed NCT04911413 - Comparison of Three Tranexamic Acid Dose Regimens in Patients Undergoing Cardiac Valve Surgery Phase 4
Completed NCT03727230 - RhD+ Blood Transfusion to Asian-type DEL Recipients N/A
Recruiting NCT06102590 - Oxygen Extraction-guided Transfusion N/A
Completed NCT00400192 - Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury N/A
Completed NCT00000593 - Viral Activation Transfusion Study (VATS) N/A
Completed NCT05581238 - Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.
Completed NCT05627544 - Blood Transfusion Applications in Hip Replacements
Not yet recruiting NCT03429790 - Cell Salvage During Caesarean Section (CSCS) N/A
Completed NCT00822588 - Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not N/A
Withdrawn NCT00269971 - A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. Phase 3
Completed NCT03930355 - Perioperative Transfusion Related Outcome